David Meeker appointed Chief Executive Officer of Rhythm Pharmaceuticals
Rhythm Pharmaceuticals have appointed David Meeker, M.D., as its Chief Executive Officer and President of the company.
Meeker succeeds interim President and CEO Hunter Smith, and adds them to his current role of Chairman of the Board of Directors. He has been in this position since 2017 and part of the board since 2015.
Hunter Smith, CFO of Rhythm, said: “I am delighted to announce David’s appointment as Rhythm’s new CEO. Since he joined our Board in 2015, David has played a key role in shaping the clinical and commercial strategy for setmelanotide and in fostering our collaborative and patient-focused culture. As we continue to work toward the first potential approval of setmelanotide in pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesities later this year, David’s extensive experience leading commercial organizations and managing the launches of new medicines for rare genetic diseases, coupled with his proven ability to build strong relationships with patient and clinician communities, will be invaluable.
“The Rhythm team is energized by the opportunity to work more closely with David in an effort to deliver setmelanotide and potentially transform the care of people living with rare genetic disorders of obesity.”
Previously, Dr Meeker had served as the CEO of KSQ Theraputics, and the Executive Vice President and Head of Sanofi Genzyme, which he joined in 1994 as its Medical Director. Over the years he served as Vice President of Medical Affairs, Chief Operating Officer, and Chief Executive Officer. Before joining Genzyme, he was Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of Medicine at Ohio State University. He earned his MD from the University of Vermont Medical School.
Commenting on his appointment, he Meeker said: ““Rhythm is an exciting company that I have long admired, both for its scientifically-rigorous approach to drug development and its commitment to patients with rare genetic disorders of obesity. With setmelanotide, we have the opportunity to bring one of the first meaningful therapeutic candidates to a segment of that community in dire need. Moreover, we hope our efforts will create visibility for rare genetic disorders of obesity, enabling better care for the people affected and catalyzing ongoing research efforts globally.
“The current management team has done a great job leading the organization through the transition and I am honored to take the CEO role.”